Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials. 27. Juli 2018 Knauf, W., Aldaoud, A., Losem, C., Mittermueller, J., Neise, M., Niemeier, B., Harde, J., Trarbach, T., Potthoff, K., 2018. Leuk. Res. 68, 90–97. doi:10.1016/j.leukres.2018.03.008 Abstract Prophylaxis of Chemotherapy-induced Neutropenia and Febrile Neutropenia with Lipegfilgrastim in Patients with Non-Hodgkin Lymphoma (NADIR study). Wolff, T., Schulz, H., Losem, C., Reichert, D., Hurtz, H.-J., Sandner, R., Harde, J., Grebhardt, S., Potthoff, K., Mueller, U., Fietz, T., 2019. Eur J… Weiterlesen MANTA – A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., Makris, A., Nemsadze, G., Brunt, A.M., Kuemmel, S., Cabrero, I.R., Perelló, A., Kendall,… Weiterlesen